Program
Budesonide
Also written as “budesonide”, “budesonide/formoterol” and “BGF MDI 320/14.4/9.6 μg”.
Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Eosinophilic Esophagitis · Colitis, Ulcerative · Glomerulonephritis, IGA, led by 35 companies.
Drug pageBudesonide: every studyMany companies study it; this page follows only the 163 they lead. All 307 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 692 open or running | phase 4since Sep 27, 2005 | Sep 13, 2005 | May 31, 2027phase 4 · NCT07073950 |
| Dr. Falk Pharmaits history only | 171 open or running | phase 3since Mar 7, 2006 | Mar 7, 2006 | Dec 2026phase 3 · NCT06596252 |
| Bausch Health Companiesits history only | 91 open or running | phase 4since Mar 17, 2020 | May 14, 2008 | Dec 2026phase 4 · NCT04314375 |
| Takedaits history only | 60 open or running | phase 3since Nov 4, 2015 | Sep 29, 2008 | none ahead |
| AbbVieits history only | 50 open or running | phase 3since Dec 5, 2007 | Oct 30, 2007 | none ahead |
| Calliditas Therapeutics ABits history only | 51 open or running | phase 4since Nov 20, 2024 | Oct 5, 2008 | Mar 2027phase 4 · NCT06712407 |
| Intech Biopharmits history only | 50 open or running | phase 2since Jun 11, 2014 | Jun 11, 2014 | none ahead |
| Chenpon Pharmaceuticalits history only | 30 open or running | phase 3since Aug 24, 2026 | Aug 24, 2026 | none ahead |
| Eurofarma Laboratoriosits history only | 30 open or running | phase 3since Oct 23, 2009 | Oct 23, 2009 | none ahead |
| Novartisits history only | 30 open or running | phase 4since Feb 15, 2013 | Feb 15, 2013 | none ahead |
| Orion Corporation, Orion Pharmaits history only | 30 open or running | phase 2since Aug 24, 2009 | Aug 24, 2009 | none ahead |
| Padagisits history only | 30 open or running | phase 3since Sep 28, 2011 | Sep 28, 2011 | none ahead |
| Aquilon Pharmaceuticalsits history only | 20 open or running | phase 2since May 31, 2021 | May 31, 2021 | none ahead |
| Bond Avillion 2 Development LPits history only | 20 open or running | phase 3since Nov 30, 2018 | Nov 30, 2018 | none ahead |
| Ferring Pharmaceuticalsits history only | 20 open or running | phase 3since Jan 22, 2018 | Jan 22, 2018 | none ahead |
| Ligand Pharmaceuticalsits history only | 20 open or running | phase 2since Jul 13, 2009 | Jul 13, 2009 | none ahead |
| Pari Pharmaits history only | 20 open or running | phase 2since Sep 4, 2013 | Sep 4, 2013 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 3since Feb 12, 2014 | Feb 12, 2014 | none ahead |
| Triastek, lnc.its history only | 22 open or running | phase 1since Oct 13, 2026 | Oct 13, 2026 | Dec 2026phase 1 · NCT07897240 |
| Vecturaits history only | 20 open or running | phase 1since Jan 12, 2018 | Jan 12, 2018 | none ahead |
| Zambon SpAits history only | 20 open or running | phase 1since Sep 2, 2014 | Sep 2, 2014 | none ahead |
| Abbottits history only | 10 open or running | phase 1since Jul 26, 2022 | Jul 26, 2022 | none ahead |
| Ache Laboratorios Farmaceuticosits history only | 10 open or running | phase 3since Jul 25, 2016 | Jul 25, 2016 | none ahead |
| Activaeroits history only | 10 open or running | phase 2since Sep 10, 2010 | Sep 10, 2010 | none ahead |
| Bazell Pharmaits history only | 10 open or running | phase 2since Jan 3, 2022 | Jan 3, 2022 | none ahead |
| Chiesi Farmaceuticiits history only | 10 open or running | phase 3since May 18, 2007 | May 18, 2007 | none ahead |
| Ciplaits history only | 10 open or running | phase 3since Mar 31, 2022 | Mar 31, 2022 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Apr 18, 2021 | Apr 18, 2021 | none ahead |
| Hamad Medicalits history only | 11 open or running | phase 3since May 25, 2015 | May 25, 2015 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 4since Oct 17, 2019 | Oct 17, 2019 | none ahead |
| Kindeva Drug Deliveryits history only | 10 open or running | phase 3since Jan 6, 2017 | Jan 6, 2017 | none ahead |
| Lunan Pharmaceutical Groupits history only | 10 open or running | no phasesince Mar 29, 2025 | Mar 29, 2025 | none ahead |
| Marinomed Biotechits history only | 10 open or running | phase 3since Nov 21, 2018 | Nov 21, 2018 | none ahead |
| Rafa Laboratoriesits history only | 10 open or running | phase 3since Aug 9, 2005 | Aug 9, 2005 | none ahead |
| Unither Pharmaceuticals, Franceits history only | 10 open or running | phase 1since Sep 6, 2024 | Sep 6, 2024 | none ahead |
Also a collaborator on its studies: Parexel, Fortrea, Takeda Development Center Americas, Iqvia Pty, Premier, Hikma Pharmaceuticals, Cosmo Technologies, MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan, Q-Pharm Pty and Kyowa Kirin.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jul 1, 2015.
- Feb 21, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT06283966 · 5,250 planned · United States, Argentina, Australia and more
- May 29, 2024Phase 1 study in Healthy VolunteerAstraZeneca · NCT06514157 · 14 enrolled · China
- Aug 19, 2024Phase 4 study in Respiratory HypersensitivityAstraZeneca · NCT06563102 · 101 enrolled · United States
- Sep 6, 2024Unither Pharmaceuticals, France’s first study: phase 1 study in HealthyNew to Unither Pharmaceuticals, FranceUnither Pharmaceuticals, France · NCT06595121 · 24 enrolled · Turkey
- Sep 11, 2024Phase 3 study in Eosinophilic EsophagitisDr. Falk Pharma · NCT06596252 · 308 enrolled · United States, Spain
- Nov 20, 2024Phase 4 study in Glomerulonephritis, IGACalliditas Therapeutics AB · NCT06712407 · 60 enrolled · United States, Puerto Rico
- Mar 29, 2025Lunan Pharmaceutical Group’s first study: no phase study in Bioequivalence Study in Healthy SubjectsNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT06924190 · 32 enrolled · China
- Jul 17, 2025Phase 4 study in Pulmonary Disease, Chronic ObstructiveAstraZeneca · NCT07073950 · 56 planned · Germany, United Kingdom
- Feb 20, 2026Phase 1 study in AsthmaAstraZeneca · NCT07433569 · 16 enrolled · United States
- Aug 24, 2026Chenpon Pharmaceutical’s first study: phase 3 study in AsthmaNew to Chenpon PharmaceuticalChenpon Pharmaceutical · NCT07790159 · 338 enrolled · China
- Aug 31, 2026Phase 2 study in AsthmaChenpon Pharmaceutical · NCT07807007 · 150 enrolled · China
- Aug 31, 2026Phase 1 study in AsthmaChenpon Pharmaceutical · NCT07804303 · 30 enrolled · China
- Oct 13, 2026Triastek, lnc.’s first study: phase 1 study in Glomerulonephritis, IGANew to Triastek, lnc.Triastek, lnc. · NCT07897240 · 18 planned · China
- Nov 3, 2026Phase 1 study in Glomerulonephritis, IGATriastek, lnc. · NCT07925216 · 18 enrolled · China
Ahead
- Dec 2026Primary completion: phase 1 study in Glomerulonephritis, IGATriastek, lnc. · NCT07897240
- Dec 2026Primary completion: phase 3 study in Eosinophilic EsophagitisDr. Falk Pharma · NCT06596252
- Dec 2026Primary completion: phase 4 study in Colitis, UlcerativeBausch Health Companies · NCT04314375
- Jan 2027Primary completion: phase 1 study in Glomerulonephritis, IGATriastek, lnc. · NCT07925216
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
| Triamcinolone Acetoniderule | clearside-biomedical-inc | phase 3 | 20 |
Studies
The newest 60 of 163 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07925216Glomerulonephritis, IGA · China | 1 | Active, not recruiting | Triastek, lnc. | Jan 2027 | 18 |
| NCT07897240Glomerulonephritis, IGA · China | 1 | Not yet recruiting | Triastek, lnc. | Dec 2026 | 18 |
| NCT07807007Asthma · China | 2 | Completed | Chenpon Pharmaceutical | Aug 3, 2026 | 150 |
| NCT07804303Asthma · China | 1 | Completed | Chenpon Pharmaceutical | Jan 22, 2024 | 30 |
| NCT07790159Asthma · China | 3 | Completed | Chenpon Pharmaceutical | Sep 27, 2024 | 338 |
| NCT07433569Asthma · United States | 1 | Completed | AstraZeneca | Jun 26, 2026 | 16 |
| NCT07073950Pulmonary Disease, Chronic Obstructive · Germany, United Kingdom | 4 | Recruiting | AstraZeneca | May 31, 2027 | 56 |
| NCT06924190Bioequivalence Study in Healthy Subjects · China | – | Completed | Lunan Pharmaceutical Group | Jan 20, 2025 | 32 |
| NCT06712407Glomerulonephritis, IGA · United States, Puerto Rico | 4 | Active, not recruiting | Calliditas Therapeutics AB | Mar 2027 | 60 |
| NCT06596252Eosinophilic Esophagitis · United States, Spain | 3 | Active, not recruiting | Dr. Falk Pharma | Dec 2026 | 308 |
| NCT06595121Healthy · Turkey | 1 | Completed | Unither Pharmaceuticals, France | Sep 16, 2024 | 24 |
| NCT06563102Respiratory Hypersensitivity · United States | 4 | Completed | AstraZeneca | Feb 24, 2026 | 101 |
| NCT06514157Healthy Volunteer · China | 1 | Completed | AstraZeneca | Sep 9, 2024 | 14 |
| NCT06283966Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Dec 3, 2027 | 5,250 |
| NCT06268301Healthy Volunteers · United States | 1 | Completed | Takeda | Feb 17, 2023 | 20 |
| NCT06245551Asthma, Exercise-Induced · Russia | 3 | Completed | AstraZeneca | Jun 29, 2024 | 64 |
| NCT06067828Pulmonary Disease, Chronic Obstructive · United States, Canada, China and more | 3 | Completed | AstraZeneca | Jan 22, 2026 | 171 |
| NCT05970263Pulmonary Disease, Chronic Obstructive | 4 | Withdrawn | AstraZeneca | Dec 31, 2025 | 0 |
| NCT05755906Asthma · United States, Canada, Czechia and more | 3 | Completed | AstraZeneca | Nov 19, 2024 | 374 |
| NCT05519514Healthy Subjects · India | 1 | Completed | Abbott | Aug 8, 2021 | 56 |
| NCT05429775Healthy Volunteers · United Kingdom | 1 | Completed | Novartis | Jan 29, 2019 | 12 |
| NCT05322707Asthma · United States | 3 | Completed | Cipla | Aug 15, 2023 | 1,485 |
| NCT05202262Asthma · United States, Canada, Germany and more | 3 | Completed | AstraZeneca | Feb 26, 2025 | 645 |
| NCT05214599Eosinophilic Esophagitis | 2 | Withdrawn | Bazell Pharma | Nov 2024 | 0 |
| NCT05148312Pharmacokinetics · Bulgaria | 1 | Completed | Aquilon Pharmaceuticals | Dec 24, 2021 | 29 |
| NCT04933383Asthma · Belgium | 2 | Completed | Aquilon Pharmaceuticals | Dec 31, 2022 | 23 |
| NCT04854538Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Oct 1, 2020 | 30 |
| NCT04609904Asthma · United States, Brazil, China and more | 3 | Completed | AstraZeneca | Mar 20, 2025 | 2,187 |
| NCT04609878Asthma · United States, Argentina, Belgium and more | 3 | Completed | AstraZeneca | Mar 21, 2025 | 2,274 |
| NCT04541043Glomerulonephritis, IGA · United States, Argentina, Australia and more | 3 | Completed | Calliditas Therapeutics AB | Feb 26, 2024 | 119 |
| NCT04494321Asthma · Taiwan | 1 | Completed | Intech Biopharm | Nov 17, 2017 | 99 |
| NCT04314375Colitis, Ulcerative · United States | 4 | Recruiting | Bausch Health Companies | Dec 2026 | 70 |
| NCT04234464Asthma, Exercise-Induced · United States | 3 | Completed | Bond Avillion 2 Development LP | Aug 28, 2020 | 60 |
| NCT04132570Rhinitis · China | 4 | Completed | Johnson & Johnson | Jan 22, 2020 | 206 |
| NCT04080713Healthy · India | 1 | Completed | Ferring Pharmaceuticals | Sep 25, 2019 | 24 |
| NCT04032834Asthma · United States | 1 | Completed | Vectura | May 22, 2017 | 34 |
| NCT03769090Asthma · United States, Argentina, Canada and more | 3 | Completed | Bond Avillion 2 Development LP | Aug 19, 2021 | 3,132 |
| NCT03755557Rhinitis, Allergic · Austria | 3 | Completed | Marinomed Biotech | Apr 5, 2019 | 82 |
| NCT03836677Pulmonary Disease, Chronic Obstructive · Belgium, Netherlands | 3 | Completed | AstraZeneca | Nov 11, 2019 | 23 |
| NCT03643965Glomerulonephritis, IGA · United States, Argentina, Australia and more | 3 | Completed | Calliditas Therapeutics AB | Jul 10, 2023 | 365 |
| NCT03412682Colitis, Ulcerative · Japan | 3 | Completed | Ferring Pharmaceuticals | May 11, 2020 | 274 |
| NCT03421730Respiratory Sounds · United States | 1 | Completed | Vectura | Mar 21, 2018 | 17 |
| NCT03245840Eosinophilic Esophagitis · United States | 3 | Terminated | Takeda | Apr 26, 2022 | 133 |
| NCT03015259Asthma · United States | 3 | Completed | Kindeva Drug Delivery | Feb 8, 2018 | 1,762 |
| NCT02972866Rhinitis, Allergic, Perennial · Brazil | 3 | Withdrawn | Eurofarma Laboratorios | Nov 2019 | 0 |
| NCT02853578Asthma · Brazil | 3 | Suspended | Ache Laboratorios Farmaceuticos | Oct 2020 | 80 |
| NCT02850484Asthma | 1 | Completed | Intech Biopharm | May 2016 | 99 |
| NCT02800824Healthy | 1 | Completed | Padagis | Jun 2016 | |
| NCT02766608Pulmonary Disease, Chronic Obstructive · United States, Canada, Czechia and more | 3 | Completed | AstraZeneca | Dec 1, 2017 | 2,389 |
| NCT02736409Eosinophilic Esophagitis · United States | 3 | Completed | Takeda | Nov 12, 2019 | 219 |
| NCT03262012Pulmonary Disease, Chronic Obstructive · Japan | 3 | Completed | AstraZeneca | Jun 15, 2018 | 416 |
| NCT03073057Asthma · Finland | 1 | Completed | Orion Corporation, Orion Pharma | Mar 2016 | 20 |
| NCT02631941Asthma · United Kingdom | 1 | Completed | Zambon SpA | Jul 2016 | 91 |
| NCT02605837Eosinophilic Esophagitis · United States | 3 | Completed | Takeda | Jan 24, 2019 | 318 |
| NCT02550418Colitis, Ulcerative · Germany | 2 | Completed | Dr. Falk Pharma | Mar 2017 | 60 |
| NCT02536508Pulmonary Disease, Chronic Obstructive · United States | 3 | Completed | AstraZeneca | Sep 12, 2017 | 627 |
| NCT02533505Pulmonary Disease, Chronic Obstructive · United States | 4 | Completed | AstraZeneca | Aug 12, 2016 | 51 |
| NCT02497001Pulmonary Disease, Chronic Obstructive · United States, Canada, China and more | 3 | Completed | AstraZeneca | Jan 5, 2018 | 1,902 |
| NCT02493335Eosinophilic Esophagitis · Germany | 3 | Completed | Dr. Falk Pharma | Nov 28, 2018 | 204 |
| NCT02495168Asthma · United States | 3 | Completed | Teva Pharmaceutical Industries | May 31, 2018 | 1,714 |
How it is read
Names in the registry
- “Budesonide”, 45 entries
- “budesonide”, 18 entries
- “budesonide/formoterol”, 10 entries
- “BGF MDI 320/14.4/9.6 μg”, 6 entries
- “BFF MDI 320/9.6 μg”, 5 entries
Conditions, from the studies’ own filings
- Asthma, 75 studies
- Pulmonary Disease, Chronic Obstructive, 23 studies
- Eosinophilic Esophagitis, 10 studies
- Colitis, Ulcerative, 9 studies
- Glomerulonephritis, IGA, 7 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.